Atrium Therapeutics Reports Preclinical Cardiac Glycogen Finding
Atrium Therapeutics says an ATR 1072 mouse surrogate reversed cardiac glycogen buildup in a preclinical study.
Related stories
Enerjisa Enerji Q3 net profit rises to 3.8 billion lira
Net profit was 958.7 million lira a year earlier.
M impact | EQUITY | Nov 02, 2026, 03:44 PM UTC
Enerjisa Enerji reports Q3 revenue
Revenue was lower than in the same period last year.
M impact | EQUITY | Nov 02, 2026, 03:40 PM UTC
Enerjisa Enerji Reports Q3 Revenue of 75.8 Billion Lira
Q3 revenue was 75.8 billion lira, versus 78.8 billion lira a year earlier.
M impact | EQUITY | Nov 02, 2026, 03:40 PM UTC
Reliance Rally and LTCG Rollback Proposal Lift Indian Stocks Nearly 2%
Reliance Industries shares had their best day since 2020, while optimism about a possible rollback of long-term capital gains tax for foreign investors accompanied gains of nearly
M impact | EQUITY | Nov 02, 2026, 03:40 PM UTC
Macquarie Focused Access Fund Launches $281.42 Million Tender Offer
M impact | EQUITY | Nov 02, 2026, 03:39 PM UTC
Loar jumps ahead of expected S&P SmallCap 600 inclusion
Loar Holdings is expected to join the S&P SmallCap 600 on Monday.
L impact | EQUITY | Nov 02, 2026, 03:39 PM UTC